It has been stated above that the commitment of the State in the field of drugs relates closely to how «obscure» the product is to the consumer. Neither the patient nor the prescriber himself have all the information required to make a rational and sufficiently judicious decision when they demand medicines. The evaluation of both the actual and total impact of any drug is too complex a process, even considering individual clinical observations. It is necessary to have available a set of qualified human, technical and financial resources to be in a position to develop an adequate pre-marketing evaluation (prior to the drug being used on a «massive» scale) and an adequate critical post-marketing follow-up (through drug surveillance programs). Since they are all highly hazardous products, society cannot take the risk of using them without such prior evaluation. This is the purpose of the regulatory approval or marketing authorization.